CLAIMS

1. A liquid pharmaceutical composition comprising an IL-15/IL-15Rα complex and about 0.0001% to about 1% (w/v) of a surfactant.
2. The composition according to claim 1, further comprising about 1 mM to about 100 mM of a buffering agent providing a pH in the range of from about 4.5 to about 8.5.
3. The composition according to claim 2, further comprising about 1 mM to about 500 mM of at least one stabilizer.
4. The composition according to any one of the preceding claims, wherein the surfactant is poloxamer.
5. The composition according to claim 4, wherein poloxamer is poloxamer 188.
6. The composition according to claim 4 or 5, wherein poloxamer is present at a concentration of about 0.05% to about 0.5% (w/v).
7. The composition according to any one of claims 1 to 3, wherein the surfactant is polysorbate.
8. The composition according to claim 7, wherein the polysorbate is polysorbate 20 or polysorbate 80.
9. The composition according to claim 7 or 8, wherein the polysorbate is polysorbate 20.
10. The composition according to claim 7 or 8, wherein the polysorbate is polysorbate 80.
11. The composition according to any one of claims 7 to 10, wherein the surfactant is at a concentration of about 0.01% to about 0.1% (w/v).
12. The composition according to any one of claims 2 to 11, wherein the buffering agent is acetate buffer, succinate buffer, citrate buffer or histidine buffer.
13. The composition according to any one of claims 2 to 12, wherein the buffering agent is acetate buffer.
14. The composition according to claim 13, wherein the acetate buffer is Na-acetate buffer.
15. The composition according to any one of claims 2 to 14, wherein the buffering agent is at a concentration of about 10 mM to about 50 mM.
16. The composition according to any one of claims 2 to 15, wherein the buffering agent is at a concentration of about 15 mM to about 30 mM.

17. The composition according to any one of claims 2 to 16, wherein the buffering agent is at a concentration of about 20 mM.

18. The composition according to any one of claims 2 to 17, wherein the buffering agent provides a pH of about 4.7 to about 5.5.

19. The composition according to any one of claims 3 to 18, wherein the at least one stabilizer is polyol or sugar.

20. The composition according to any one of claims 3 to 19, wherein the at least one stabilizer is a sugar that is sucrose.

21. The composition according to any one of claims 3 to 20, wherein at least one stabilizer is present at a concentration of about 100 mM to about 350 mM.

22. The composition according to any one of claims 3 to 21, wherein at least one stabilizer is present at a concentration of about 220 mM to about 300 mM.

23. The composition according to any one of claims 3 to 22, wherein at least one stabilizer is present at a concentration of about 260 mM.

24. The composition according to any one of the preceding claims, wherein the concentration of the IL-15/IL-15Rα complex is about 0.1 mg/mL to about 50 mg/mL.

25. The composition according to any one of the preceding claims, wherein the concentration of the IL-15/IL-15Rα complex is about 0.1 mg/mL to about 10 mg/mL.

26. The composition according to any of the preceding claims, comprising about 1 mg/mL of IL-15/IL-15Rα complex, about 0.2% Poloxamer 188, about 260 mM Sucrose, about 20 mM Na-Acetate, and a pH of about 5.0.

27. A solid pharmaceutical composition comprising an IL-15/IL-15Rα complex and about 10 mM to about 50 mM of a buffering agent providing a pH in the range of from about 6.5 to about 8.5, about 1 mM to about 500 mM of at least one stabilizer and about 0.1 mM to about 50 mM of at least one tonicity agent.

28. The composition according to claim 27, wherein the buffering agent is phosphate buffer, acetate buffer, succinate buffer, citrate buffer or histidine buffer.

29. The composition according to any one of claims 27 to 28, wherein the buffering agent is Na/K phosphate buffer.

30. The composition according to any one of claims 27 to 29, comprising about 1 mM to about 50 mM buffering agent.

31. The composition according to any one of claims 27 to 30, comprising about 1 mM to about 5 mM buffering agent.

32. The composition according to any one of claims 27 to 31, wherein the pH of the composition is about 6.5 to about 7.5

33. The composition according to any one of claims 27 to 32, wherein the pH of the composition is about 7.3.

34. The composition according to any one of claims 27 to 33, further comprising about 1 mM to about 500 mM of at least two stabilizers.

35. The composition according to any one of claims 27 to 34, comprising about 1 mM to about 500 mM sucrose and about 1 mM to about 500 mM mannitol.

36. The composition according to any one of claims 27 to 35, comprising about 5 mM to about 50 mM sucrose and about 100 mM to about 300 mM mannitol.

37. The composition according to any one of claims 27 to 36, comprising about 30 mM sucrose and about 220 mM mannitol.

38. The composition according to any one of claims 27 to 37, further comprising about 0.1 mM to about 50 mM of at least two tonicity agents.

39. The composition according to any one of claims 27 to 38, comprising about 0.1 mM to about 50 mM KCl and about 0.1 mM to about 50 mM NaCl.

40. The composition according to any one of claims 27 to 39, comprising about 0.1 mM to about 1 mM KCl and about 10 mM to about 50 mM NaCl.

41. The composition according to any one of claims 27 to 40, comprising about 0.375 mM KCl and about 20 mM NaCl.

42. The composition according to any one of claims 27 to 41, comprising about 0.1 mg/mL to about 50 mg/mL of IL-15/IL-15Rα complex.

43. The composition according to any one of claims 27 to 42, comprising about 0.1 mg/mL to about 10 mg/mL of IL-15/IL-15Rα complex.

44. The composition according to any one of claims 27 to 43, comprising about 0.1 mg/mL to about 0.5 mg/mL of IL-15/IL-15Rα complex.

45. The composition according to any one of claims 27 to 44, wherein the composition is lyophilized.

46. The composition according to any one of claims 27 to 45, comprising about 0.24 mg/mL IL-15/IL-15Rα complex, about 30 mM sucrose, about 220 mM mannitol, about 0.375 mM potassium chloride, about 20 mM NaCl, about 1.35 mM Na/K phosphate buffer at pH of about 7.3.

47. The composition according to any one of the preceding claims, wherein the IL-15/IL-15Rα complex comprises IL-15 comprising SEQ ID NO: 2.

48. The composition according to any one of the preceding claims, wherein the IL-15/IL-15Rα complex comprises IL-15Rα comprising SEQ ID NO: 5.

49. The composition according to any one of the preceding claims, wherein the IL-15/IL-15Rα complex comprises IL-15 comprising SEQ ID NO: 2 and IL-15Rα comprising SEQ ID NO: 5.

50. The composition according to any one of claims 1-49 for use in the treatment of cancer, lymphopenia, immunodeficiencies, infectious diseases, and/or wounds.

51. The composition according to claim 50 for use in the treatment of cancer.

52. The composition according to claim 50 or 51, wherein the cancer is bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastro-esophageal, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Merkel cell cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, multiple myeloma, myelodysplastic syndromes, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos (e.g. mesothelioma), and combinations of said cancers.

53. The composition according to any of claims 50 to 52, wherein the cancer is melanoma, renal cancer, colon cancer, or prostate cancer.

54. The composition according to any of claims 50 to 53, wherein the cancer is melanoma.

55. The composition according to any of claims 50 to 54, wherein cancer is metastatic.

56. A dosage form comprising the pharmaceutical composition of any one of claims 1 to 49.

57. A vial comprising the pharmaceutical composition according to any one of claims 1 to 49.

58. A syringe comprising the pharmaceutical composition according to any one of claims 1 to 49.

59. An autoinjector comprising the syringe of claim 58.

60. An autoinjector comprising the composition according to any of claims 1-49.

61. The composition according to any one of claims 1-26, wherein the liquid composition maintains:

a. about 0.1% to about 0.25% sum of aggregates upon storage at 2-8°C for 24 weeks;

b. about 0.15% to about 0.35% sum of aggregates upon storage at 25 ºC for 12 weeks;

c. about 0.3% to about 0.6% sum of aggregates upon storage at 40ºC for 6 weeks;

d. about 0.25% to about 0.75% sum of fragments upon storage at 2-8°C for 24 weeks;

e. about 1.5% to about 2.0% sum of fragments upon storage at 25 ºC for 12 weeks;

f. about 2.5% to about 3.5% sum of fragments upon storage at 40ºC for 6 weeks;

g. about 42.5% to about 45% sum of basic variants upon storage at 2-8°C for 24 weeks;

h, about 55% to about 57.5% sum of acid variants storage at 2-8°C for 24 weeks;

i about 38% to about 42% sum of basic variants upon storage at 25ºC for 12 weeks;

j. about 55% to about 60% of acidic variants upon storage at 25ºC for 12 weeks;

k. about 65% to about 67% of IL-15Rα by CE-SDS upon storage at 2-8°C for 24 weeks;

l. about 17% to about 19% of IL-15 by CE-SDS upon storage at 2-8°C for 24 weeks;

m. about 7% to about 8% of IL-15 HMW by CE-SDS upon storage at 2-8°C for 24 weeks;

n. about 5% to about 6% aglycosylated IL-15 by CE-SDS upon storage at 2-8°C for 24 weeks;

o. about 2% to about 4% sum of impurities by RP-HPLC upon storage at 2-8°C for 24 weeks;

p. about 3% to about 5% sum of impurities by RP-HPLC upon storage at 25ºC for 12 weeks;

q. below 5% sum of impurities by RP-HPLC upon storage at 40ºC for 6 weeks;

r. substantially no SVP >2μm by PAMAS upon storage at 2-8°C for 24 weeks;

s. substantially no SVP >10μm by PAMAS upon storage at 2-8°C for 24 weeks;

t. below 1.0 NTU turbidity upon storage at 2-8°C for 24 weeks;

u. below 0.25% sum of aggregates assessed by SEC after being subjected to five freeze/thaw cycles or overnight shaking; or

v, below 0.35% sum of fragment assessed by SEC after being subjected to five freeze/thaw cycles or overnight shaking.